Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

102.89
+1.291.27%
Post-market: 102.890.00000.00%19:31 EDT
Volume:650.45K
Turnover:66.78M
Market Cap:5.08B
PE:-17.83
High:103.83
Open:101.13
Low:100.00
Close:101.60
Loading ...

Sector Update: Health Care Stocks Steady Premarket Monday

MT Newswires Live
·
09 Jun

Axsome Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
09 Jun

Axsome Therapeutics Inc : Needham Cuts Target Price to $150 From $153

THOMSON REUTERS
·
09 Jun

Axsome Therapeutics Shares Down 4.4% Premarket After FDA Refuses to Review Co's Application for Fibromyalgia Drug

THOMSON REUTERS
·
09 Jun

Axsome Therapeutics Receives Refusal to File Letter from FDA for AXS-14 NDA in Fibromyalgia Management, Plans Additional Trial to Address Feedback

Reuters
·
09 Jun

Axsome Therapeutics Inc - to Conduct Additional Controlled Trial for Axs-14 in Q4 2025

THOMSON REUTERS
·
09 Jun

Axsome Therapeutics Inc - Receives Refusal to File Letter From FDA for Axs-14

THOMSON REUTERS
·
09 Jun

Axsome Therapeutics Provides Update on the New Drug Application (Nda) for Axs-14 for the Management of Fibromyalgia

THOMSON REUTERS
·
09 Jun

Axsome Therapeutics Inc - FDA Finds Nda for Axs-14 Insufficiently Complete for Review

THOMSON REUTERS
·
09 Jun

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Apellis Pharmaceuticals (APLS) and Bio-Rad Laboratories (BIO)

TIPRANKS
·
09 Jun

Axsome Therapeutics Headed for Positive Growth With Ample Pipeline , Oppenheimer Says in New Research

MT Newswires Live
·
04 Jun

Axsome Therapeutics Inc. COO Mark Jacobson Reports Disposal of Common Shares

Reuters
·
29 May

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Axsome Therapeutics (AXSM)

TIPRANKS
·
29 May

Axsome Therapeutics Reaches Settlement in SUNOSI Patent Litigation with Hetero Labs

Reuters
·
27 May

Axsome Therapeutics Settles Sunosi® (Solriamfetol) Patent Litigation With Hetero Labs Ltd.

THOMSON REUTERS
·
27 May

Axsome - Hetero to Sell Generic Sunosi From Sept 1, 2040 IF Pediatric Exclusivity Is Granted for Sunosi

THOMSON REUTERS
·
27 May

Strong Commercial Trajectory and Growth Potential Justify Buy Rating for Axsome Therapeutics

TIPRANKS
·
26 May

Axsome Therapeutics Price Target Maintained With a $180.00/Share by HC Wainwright & Co.

Dow Jones
·
22 May

Director Mark Coleman Reports Disposal of Common Shares of Axsome Therapeutics Inc

Reuters
·
21 May

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Waters (WAT) and Cingulate Inc (CING)

TIPRANKS
·
19 May